Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-study-reveals-risk-of-liver-related-complications-but-not-liver-cancer-decreases-over-time-in-patients-who-have-recovered-from-hepatitis-b-regular-cancer-surveillance-is-recommended
https://www.med.cuhk.edu.hk/press-releases/cuhk-study-reveals-risk-of-liver-related-complications-but-not-liver-cancer-decreases-over-time-in-patients-who-have-recovered-from-hepatitis-b-regular-cancer-surveillance-is-recommended
CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

About 540,000 cases of hepatitis B infection have been identified in Hong Kong. Clinical practitioners have found that some chronic hepatitis B patients achieve seroclearance of the hepatitis B surface antigen (HBsAg), which means recovery from hepatitis B, with or without using medication. The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) analysed 12-year data of about 10,000 patients who had recovered from hepatitis B and found that the risk of hepatic decompensation, or liver-related complications, for these patients decreased over time. The risk of hepatic decompensation among those without cirrhosis at the time of recovery was only 0.05% after seven years. However, the hepatocellular carcinoma (liver cancer) risk persisted in the recovered patients. The research team recommends regular cancer surveillance in patients who have recovered from hepatitis B. The results have been published in the international medical journal The Journal of Hepatology.   

 

Professor Grace Wong

Professor Grace Wong

Early understanding of clinical outcomes after hepatitis B recovery helps provide the appropriate care to patients

 

Hepatitis B infection is the major cause of liver cirrhosis and liver cancer. Professor Grace Wong Lai-hung, Professor of the Division of Gastroenterology and Hepatology at CU Medicine’s Department of Medicine and Therapeutics, stated, “Hepatitis B is generally considered treatable but not curable. In fact, some patients can achieve seroclearance of HBsAg, which is regarded as being functionally cured in patients with chronic hepatitis B. While novel hepatitis B infection treatments aimed at increasing functional cure rates are under active development, it is important to understand the clinical course of patients following HBsAg seroclearance, to provide them with the appropriate care as well as to better allocate resources.”   

 

CU Medicine’s research team analysed the data of about 10,000 functionally cured hepatitis B patients identified between 2000 and 2020. Results showed that the incidence of hepatocellular carcinoma and of hepatic decompensation including ascites and hepatic encephalopathy remained low in the first seven years after HBsAg loss. The latter further decreased after seven years after HBsAg loss, while the former did not. Here are the details:

 

Average annual incidence of hepatic decompensation

Average annual incidence of hepatocellular carcinoma

HBsAg loss in the first seven years

0.26%

0.20%

HBsAg loss in eight to 12 years

0.12%

0.19%

 

Dr Terry Yip

Dr Terry Yip

Advanced age, being male, presence of cirrhosis and low platelet count are risk factors of liver cancer

 

First author of the study Dr Terry Yip Cheuk-fung, Assistant Professor of the Department of Medicine and Therapeutics at CU Medicine, remarked, “Our data shows that the risk of hepatic decompensation is significantly reduced after hepatitis B recovery. But patients should still be cautious and receive long-term and regular cancer surveillance, especially those with risk factors.” Dr Yip added that his team’s analysis confirmed that advanced age, being male, a low platelet count and the presence of cirrhosis affect the long-term clinical outcomes of the recovered patients. For example, patients with cirrhosis at the time of HBsAg loss have a higher risk of hepatic decompensation and hepatocellular carcinoma than those without cirrhosis. Details are tabulated as follows:

 

HBsAg loss in the first seven years

Average annual incidence of hepatic decompensation

Average annual incidence of hepatocellular carcinoma

Patients without cirrhosis

0.14%

0.14%

Patients with cirrhosis

1.20%

0.57%

HBsAg loss in eight to 12 years

Average annual incidence of hepatic decompensation

Average annual incidence of hepatocellular carcinoma

Patients without cirrhosis

0.05%

0.12%

Patients with cirrhosis

0.53%

0.56%

 

Professor Vincent Wong

Professor Vincent Wong

Professor Vincent Wong Wai-sun, Head of the Division of Gastroenterology and Hepatology and Mok Hing Yiu Professor of Medicine at CU Medicine’s Department of Medicine and Therapeutics, concluded, “Given the increased therapeutic options in the coming five to eight years, we anticipate that the proportion of patients achieving HBsAg loss will increase. Novel hepatitis B infection therapeutics should be offered to patients early once available, because the earlier the functional cure, the lower the risk of hepatic decompensation in their lifetime. Cancer surveillance should also be provided to functionally cured patients who are at risk.”

 

More Press Releases

CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

Research
CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research
CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and  inpatient progression in older patients living in nursing homes

CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and inpatient progression in older patients living in nursing homes

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

Research
CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

Research
CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

Research
Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Research
CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

Research
CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

Research
CUHK Reveals Hepatitis B Prevalence Among Pregnant Women Remains High Despite More Than 25 Years of Universal Hepatitis B Vaccination

CUHK Reveals Hepatitis B Prevalence Among Pregnant Women Remains High Despite More Than 25 Years of Universal Hepatitis B Vaccination

Research
CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

Research
CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

Health Campaign
CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

Research
CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

Awards and honors
CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

Research
CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

Research
CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.